Moleculin Biotech Inc., of Houston, said responses to the FDA's requests for additional information relating to a physician-sponsored IND to study WP-1066, a STAT3 inhibitor, in brain tumors has been submitted. The planned phase I study is expected to study WP-1066 in patients with glioblastoma or melanoma.